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Abstract
Background: The concept of osteoarthritis (OA) heterogeneity is evolving and gaining renewed interest. According
to this concept, distinct subtypes of OA need to be defined that will likely require recognition in research design
and different approaches to clinical management. Although seemingly plausible, a wide range of views exist on
how best to operationalize this concept. The current project aimed to provide consensus-based definitions and
recommendations that together create a framework for conducting and reporting OA phenotype research.
Methods: A panel of 25 members with expertise in OA phenotype research was composed. First, panel members
participated in an online Delphi exercise to provide a number of basic definitions and statements relating to OA
phenotypes and OA phenotype research. Second, panel members provided input on a set of recommendations for
reporting on OA phenotype studies.
Results: Four Delphi rounds were required to achieve sufficient agreement on 11 definitions and statements.
OA phenotypes were defined as subtypes of OA that share distinct underlying pathobiological and pain
mechanisms and their structural and functional consequences. Reporting recommendations pertaining to the
study characteristics, study population, data collection, statistical analysis, and appraisal of OA phenotype studies
were provided.
Conclusions: This study provides a number of consensus-based definitions and recommendations relating
to OA phenotypes. The resulting framework is intended to facilitate research on OA phenotypes and
increase combined efforts to develop effective OA phenotype classification. Success in this endeavor will
hopefully translate into more effective, differentiated OA management that will benefit a multitude of OA
patients.
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Background
There has been longstanding acceptance of the hetero-
geneity of osteoarthritis (OA), but this topic is attracting
increasing interest given an expanding armamentarium
for classification (biological, psychosocial, and statistical);
new insights into the pathophysiology, prognosis, and
patterns of response to new and existing interventions;
and a general move towards personalized care to im-
prove efficiency and effectiveness [1]. A specific develop-
ment more recently has been to invoke the concept of
OA phenotypes. According to this concept, OA is com-
posed of a number of phenotypes that may be present to
a varying extent among patients spanning the spectrum
of disease [2]. These phenotypes may differ in their com-
patibility with study designs in research and diagnostic
and therapeutic strategies in clinical care. Although
seemingly plausible, a wide range of views exist on how
best to operationalize this concept, and similarly, a variety
of approaches have been used to explore heterogeneity in
empirical studies. Studies focused on OA phenotypes pub-
lished up to day differ in approach, criteria to distinguish
phenotypes, and their outcomes. Furthermore, different
papers used different and sometimes confusing terminolo-
gies. A more consistent use of terminology would increase
the synergy between studies and facilitate the progress of
the field as a whole. Furthermore, to allow effective com-
parison between studies and meta-analyses, complete
reporting of relevant data is important.
In the field of back pain, the pathway from basic
research to successful phenotyping has been argued as
composing of a number of steps [3]. First, there are
studies of assessment methods that could potentially
provide important data on one or more phenotypes. For
example, one may develop a new imaging technique to
assess the glycosaminoglycan content of articular cartilage.
Second, hypothesis-generating studies aim to determine
which characteristics identify people in clinically import-
ant subgroups. For example, a biochemical marker level
could be higher in a particular subgroup of knee OA
patients. Third, hypothesis-testing studies test a priori
hypotheses about subgrouping effects in samples of people
independent from, but similar to, those people involved in
the hypothesis-setting phase. Studies in this phase typic-
ally follow a more stringent approach than those at the
hypothesis-generating stage. For example, the biochemical
marker is now evaluated in a larger, well-characterized pa-
tient sample and might include healthy controls. Fourth,
relatively narrow validation studies attempt to replicate
findings of hypothesis-testing studies in independent sam-
ples of people who are similar to those originally studied.
Fifth, broader validation studies try to replicate the find-
ings of hypothesis-generating studies in independent sam-
ples from broader populations than those originally tested.
For example, the biochemical markers for phenotyping
OA patients in specialist outpatient clinics would be tested
in a primary care setting. Sixth and last, impact-analysis
studies examine the capacity of a specific phenotyping
method in routine care settings to change clinical
decision-making, improve patient outcomes, and/or in-
crease health system efficiency.
The current project aimed to provide a widely sup-
ported framework for designing and conducting research
along the pathway from basic research to successful clin-
ical application of OA phenotyping, through consensus
on a number of definitions and conceptual statements
and a set of reporting recommendations. Ultimately, if
adopted widely, this should contribute to a more coordi-
nated research effort.
Methods
The framework consisted of two main parts. First, a
panel of researchers with expertise in OA phenotype
research commented on a number of basic definitions
and conceptual statements in an online Delphi exercise.
Second, the panel provided input on reporting recom-
mendations in a face-to-face meeting.
Panel composition
The panel consisted of 25 members. Panel members
were selected to encompass an array of expertise in OA
related topics, career stages, and geographical origins.
Each of the members had demonstrable experience in
phenotype research, as became evident from publica-
tions in peer-reviewed scientific journals. The panel was
composed and led by a core group (WEvS, SBZ, LAD,
DJH).
Basic definitions and statements
We used the Delphi Decision Aid hosted on the
ForecastingPrinciples.com website that was originally de-
veloped by J. Scott Armstrong (University of Pennsylvania).
It is managed by Kesten C. Green (University of South
Australia), and the software is maintained by Saint Louis
Integration (stlouisintegration.com).
An initial set of statements was developed by the core
group. Statements were based on points that became
apparent from literature data on OA phenotypes [1, 4]
and phenotype studies in other diseases [3, 5]. All panel
members were then invited to score every statement on
a range from 0 to 100% (0% meaning no agreement and
100% meaning complete agreement) and provide com-
ments to explain and contextualize the scores. They
could also suggest additional statements. For each subse-
quent round, statements were adapted by the core group
in response to scores and comments. In this process,
some statements were combined and others split up.
Rounds were continued until all statements scored ≥
80% on average.
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Panel members were provided with a document show-
ing anonymized scores and comments from previous
Delphi rounds (Additional file 1). The document also ex-
plained how and why statements were adapted between
rounds. For any particular round, panel members were
not aware of scores and comments from other panel
members during the time the round was open.
Reporting recommendations
Based on similar initiatives for research publications in
general, or in other fields, a set of reporting recommen-
dations was compiled by the core group [6–8]. These
recommendations were discussed in a meeting with
panel members on 29 April 2018 and adapted using the
synthesis of these discussions. Members who could not
attend the meeting were given the opportunity to pro-
vide input via email.
Results
Basic definitions and statements
Four Delphi rounds were required to achieve sufficient
agreement on 11 statements (see Tables 1 and 2). OA
phenotypes were defined as subtypes of OA that share
distinct underlying pathobiological and pain mechanisms
and their structural and functional consequences. This
and some of the other concepts in the statements are
also summarized in Fig. 1.
Every OA phenotype encompasses a number of typical
pain and/or pathobiological mechanisms. People with
OA can be assessed for the presence of one or more pa-
rameters that reflect these mechanisms. Every person
can have characteristics of one or more phenotypes.
Every OA phenotype relates to characteristic clinical and
structural outcomes and, with that, to the effectiveness
of particular interventions.
Reporting recommendations
Twelve panel members attended the face-to-face meet-
ing. All panel members were given the opportunity to
provide input via email. Reporting recommendations
that followed from the panel meeting are summarized in
Table 3 and discussed below. These recommendations
are anticipated to be useful for authors, reviewers, and
editors in the process of writing, reviewing, and publish-
ing reports. Importantly, these criteria are not to be used
as quality markers, as at this point, there are insufficient
data to support any such decisions. Likewise, it was
decided that there were not enough data to support the
weighting of individual items. Finally, it is important to
emphasize that these recommendations are in no way
intended to restrict researchers in their approach to
identifying OA phenotypes or determine overlaps be-
tween them.
General study characteristics
Currently, most datasets used for OA phenotype re-
search are datasets from other studies or trials that are
then secondarily used for phenotyping. Knowledge about
the setting and characteristics of the original study are
important for proper interpretation of the outcomes of
the subsequent phenotype analysis. The original study
goals and design will determine the contents of the data-
set and the potential outcomes of the phenotype ana-
lyses. For example, opportunities for phenotype analysis
in a dataset that is originated from a clinical trial will be
different from analyses performed with data from an
observational study. In keeping with this concept, some
researchers may investigate phenotypes that differ in
response to treatment, while others may explore pheno-
types that differ in natural disease course.
Study population
The characteristics of the study population are import-
ant to take into account when interpreting the validity of
the results of the OA phenotype analysis and for com-
paring results between studies. For example, the poten-
tial to identify particular phenotypes might be different
between populations with and without OA pain or be-
tween patients from general practice and orthopedic
clinics. Likewise, non-random subject selection or drop-
out in observational or interventional studies can affect
the study results. For example, a phenotype that is non-
responsive to a particular treatment in a clinical trial
might show higher dropout rates and thereby provide
less follow-up data for subsequent phenotype analysis.
Data collection
It is likely that every phenotype will be characterized by
one or more parameter prognostic factors relating to
one or more pathobiological or pain mechanisms that
are critical for that particular phenotype. Usually, there
are multiple ways to assess and/or monitor OA and
Table 1 Overview of the Delphi rounds
Round 1 16 statements 16 January to 25 February 2018 22 respondents
Round 2 12 statements 15 February to 12 March 2018 21 respondents
Round 3 11 statements 21 March to 21 April 2018 21 respondents
Round 4 6 statements 13 June to 5 July 2018 20 respondents
Overview of the four Delphi rounds that were run in total. For every round, it is shown how many statements were open for scoring in that round, the period it
was open, and how many of the total of 25 panel members responded
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Table 2 Final statements on OA phenotypes
Number Statement Mean score Distribution of scores
(minimum—25%
percentile—75%
percentile—maximum)
1 OA phenotypes are subtypes of OA that share distinct underlying pathobiological
and pain mechanisms and their structural and functional consequences.
86 60—80—94—100
2 OA phenotypes can become apparent in differences in risk factors, prognostic factors,
nature and extent of symptoms and signs, disease trajectory, and/or responsiveness
to particular treatments or treatment in general.
89 70—80—99—100
3 An OA phenotype classification system is likely to consist of input variables that
together reflect (the likelihood of) the presence of one or more pathobiological and
pain mechanisms.
88 70—80—94—100
4 Classification systems are likely to use one or more measures from either one or
more domains (e.g., imaging markers, biochemical markers, and pain) to identify a
clinically relevant OA phenotype or phenotypes.
86 60—80—95—100
5 The potentially identified phenotype(s) should differ from others in terms of clinically
relevant disease-driving factors and/or outcomes.
87 50—80—99—100
6 Research efforts may initially lead to multiple proposed phenotype classification systems.
Eventually, these should be aligned and come together in one.
84 65—72—94—100
7a Differences in the disease stage may cause different results from OA phenotyping
studies between study populations. It is likely that the nature and course of disease
stages may differ between patients and phenotypes.
82 50—80—90—100
7b Disease stage(s) of the study population should always be reported. Reasons to take
or not take disease stage into account in the analyses (e.g., to adjust for confounding
or look for interaction) should be weighted for every study.
84 50—80—99—100
8a Some components of pathobiological and pain mechanisms in OA may be similar
between different joints such as knee and hip (e.g., synovitis, central pain perception),
while others may differ (e.g., menisci, femoral head shape). The decision to extrapolate
findings from one joint to another, or not, should be justified.
86 50—80—94—100
8b Phenotype classification systems can be designed for individual joints or systemically
(e.g., for multiple joints in one patient), depending on the pathobiological and pain
mechanism that is under study and the goal of the study.
86 70—80—90—100
9 Data-driven approaches for constructing phenotype classification systems are generally
preferable over expert opinion-based approaches, as long as they are performed using
high-quality data and appropriate statistics, are reproducible, and have clinical validity,
relevance, and applicability as judged by experts in the field.
91 70—86—100—100
Overview of the final statements that resulted from the Delphi exercise. The level of agreement among panel members is indicated for every statement by the
mean score (0% meaning no agreement and 100% meaning complete agreement) and the distribution of individual scores
Fig. 1 Schematic overview of the general concept behind a number of the statements from the Delphi exercise
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these may differ importantly in their ability to reflect the
pathogenetic and/or pain mechanisms of interest and in
their technical characteristics (e.g., accuracy, precision,
reproducibility). Therefore, it is considered important
that strengths and weaknesses of the available set of
parameters for the phenotype analysis are understood
and discussed. For example, subchondral bone structure
can be assessed by different imaging techniques and
these may or may not be supplemented with biochem-
ical markers of bone metabolism. Biochemical markers
might, however, be less specific for the joint tissue of
interest or be more subject to noise. The available
follow-up time and number of time points may also
affect the ability of parameters to differentiate between
potential phenotypes. For example, biochemical markers
compared with imaging markers might be more dynamic
and require shorter follow-up times to show differences
in disease course or treatment response between
phenotypes.
Statistical analysis
The panel members considered data-driven approaches
valuable for gaining insights into OA phenotypes that
extend beyond current knowledge. However, data-driven
approaches are often rather sensitive to changes in the
particular features of the analysis (e.g., a clustering
method, number of subgroups, methods to handle miss-
ing data) and selection bias. The features may be fine-
tuned in an iterative process whereby outcomes are
compared back and forth between settings. This process
may be more or less subjective and/or be performed ac-
cording to prespecified criteria. Irrespective of the ap-
proach, the clinical relevance of the potentially identified
phenotypes should be accounted for in the analysis plan.
For example, differences in pain course between pheno-
types should be clinically meaningful. Sensitivity analyses
(e.g., repeated analysis with different cutoffs) and
methods to describe consistency and reproducibility
(e.g., internal or external validity) are considered particu-
larly important for data-driven techniques. Access to the
dataset(s) and syntax(es) for other investigators to repeat
and/or extend analyses is encouraged.
Appraisal
For an identified OA subgroup to be considered a dis-
tinct phenotype, the extent to which its main underlying
pathobiological or pain mechanism(s) can be assumed to
differ from others should be made clear. Explaining
similarities and differences in relation to the existing
literature may highlight consistency of findings across
studies and/or point out how observable differences
might have occurred. It is also advised to discuss how
the identified phenotype(s) might impact future research
Table 3 Reporting recommendations
General study characteristics
Availability of a prespecified research protocol
Study design: observational cohort, case-control, clinical trial, animal study,
other
Primary goal and setup of the original study, when the phenotype approach is
not the primary goal of the study. Cite references/registrations when available
Intended goal(s) and context(s) of the pursued phenotype classification (e.g., to
have prognostic or therapeutic consequences)
Position of the study with respect to its stage in phenotyping (i.e., study of
assessment method, hypothesis-setting, hypothesis-testing, narrow validation,
broad validation or impact analysis)
Study population
Setting: general population, general practitioner, rheumatological and/or
orthopedic practice, etc.
Flow diagram of participants selection process/sampling
Sample size, dropouts
Demographics
Clinical OA characteristics (e.g., pain, function)
Structural OA characteristics (e.g., radiographic parameters)
Data collection
Variable(s) for the assumed pathobiological and/or pain mechanisms under
study
• Explanation of how and why the variable(s) is (are) anticipated to reflect the
mechanism(s)
• Statement of the quality of the variable(s), when available
Follow-up time points for each of the variables (longitudinal studies)
Outcome parameter(s) (i.e., structural and functional consequences of the
phenotype(s))
Statistical analysis
Availability of a prespecified statistical analysis plan
Analytical approach (supervised, unsupervised*) and rationale
Power, sample size considerations
Methods to adjust for potential confounders/effect modifiers and to handle
missing data
Criteria for the distinction between phenotypes and whether these were
predefined
Criteria for clinical relevance and/or applicability and whether these were
predefined
Any sensitivity analyses
Methods to determine reproducibility/consistency
Availability of datasets and syntaxes to other investigators (e.g., website, contact
details)
Appraisal
Underlying pathobiological and/or pain mechanisms
Potential clinical relevance and applicability
Internal validity, potential sources of bias
External validity, generalizability
Comparison with other phenotype classifications/literature data, when possible
Relevance and consequences of the present work for future research
Financial/commercial interests, funding sources
*Supervised statistical methods require output variables to be available and
serve to estimate functions that best approximate the relationship between
the input and output variables in the dataset (e.g., linear regression).
Unsupervised statistical methods are not provided with output variables but
are concerned with uncovering structures within datasets without prior
knowledge of how the data are organized (e.g., principal component analysis)
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and practice (e.g., external validity, potential therapeutic
consequences).
Discussion
This OA phenotype framework is intended to facilitate
research on OA phenotypes and increase combined ef-
forts to attain effective OA phenotype classification,
through providing a number of coherent definitions and
statements and a set of reporting recommendations that
were supported by a panel of researchers with relevant
expertise. The provided framework got focused around
distinct pathobiological and/or pain mechanisms. This
focus is in line with the ultimate goal to develop
phenotype-specific interventions, targeted at these dis-
tinct mechanisms. A number of studies argue in favor of
the actual existence of subgroups with distinct pathobio-
logical and/or pain mechanisms [9–12]. Further success
in this endeavor depends on the adoption of the cur-
rently proposed framework in the field. This will hope-
fully translate into more effective, differentiated OA
management that will benefit a multitude of OA pa-
tients. Although we aimed to codify a representative set
of shared opinions of individuals working in the field of
OA phenotypes, we realize that insights will no doubt
evolve over time and that updating the framework will
likely be required in the future as the field matures and
more data will become available. The ultimate success of
such an initiative will require consistent and wide
implementation.
Conclusions
A wide range of views exist on how best to operationalize
the concept of OA phenotypes. The current initiative pro-
vides consensus-based definitions, statements, and report-
ing recommendations to the OA phenotype research field,
supported by an international panel of researchers with
relevant expertise. Implementation of these is considered
important to standardize and synergize the wide range of
research activities that are currently being deployed in
this multidisciplinary field. Success in this endeavor
will hopefully translate into the consistent identifica-
tion of distinct phenotypes and more effective, differ-
entiated OA management.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13075-020-2143-0.
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